Biotechnology Value Trading Fund OS LP
CIK 1660683 · last filed 2025-05-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$555.86M
Companies
14
Total Filings
20
Lifetime Open-Market Net
-$1.22B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XOMAP | 1,322,758 | $24.98 | $33.04M | -$106.43M | 1 | 2025-05-20 | |
| KYMR | Director | 1,888,351 | $106.16 | $200.47M | $0 | 1 | 2023-06-20 |
| GPCR | 0 | $47.89 | $0 | $0 | 1 | 2023-05-12 | |
| Repare Therapeutics Inc. (RPTX) Delisted | 3,299,906 | $2.65 | $8.74M | $18.99M | 1 | 2022-06-15 | |
| CGEM | 364,161 | $17.47 | $6.36M | $82.65M | 1 | 2022-06-03 | |
| CTI BIOPHARMA CORP (CTIC) Delisted | 3,102,435 | $9.09 | $28.20M | $50.00M | 2 | 2021-04-05 | |
| Merus N.V. (MRUS) Delisted | 3,513,335 | $90.00 | $316.20M | $209.06M | 1 | 2021-01-25 | |
| CYTK | 2,777,320 | $79.45 | $220.66M | $0 | 1 | 2020-11-20 | |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 670,695 | $38.00 | $25.49M | -$1.49B | 2 | 2020-11-13 | |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 32,062 | $15.70 | $503.4K | $25.65M | 1 | 2020-11-03 | |
| XOMA | 2,022,816 | $40.17 | $81.26M | $4.31M | 3 | 2020-09-10 | |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | 952,859 | $8.37 | $7.98M | -$28.94M | 1 | 2019-06-12 | |
| XENE | 216,694 | $64.94 | $14.07M | $0 | 1 | 2018-03-29 | |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 2,968,487 | $0.04 | $132.7K | $14.06M | 1 | 2017-10-05 |
Recent Filings · Page 2 of 2
20 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-20 | CYTK | Other (J) | — | $0 | EDGAR |
| 2020-11-13 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Sell (S) | −73,933,400 | -$1.49B | EDGAR |
| 2020-11-03 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +9,326,120 | $25.65M | EDGAR |
| 2020-09-10 | XOMA | Buy (P) | +77,370 | $1.45M | EDGAR |
| 2020-04-17 | XOMA | Conv (C) | +12,527,720 | $162.86M | EDGAR |
| 2019-10-31 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +205,198 | $796.7K | EDGAR |
| 2019-06-12 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Sell (S) | −2,704,023 | -$28.94M | EDGAR |
| 2019-05-14 | XOMA | Buy (P) | +195,391 | $2.86M | EDGAR |
| 2018-03-29 | XENE | Other (J) | −17,059,000 | $0 | EDGAR |
| 2017-10-05 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +11,200,322 | $14.06M | EDGAR |
Showing 11–20 of 20
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.